miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review
Abstract
:1. Introduction
2. Multiple Sclerosis
3. miRNA, Facts, and Expectations
4. miR-155 and Immune Response
5. miR-155 and Blood–Brain Barrier
6. miR-155 and Demyelination
7. miR-155 and Neuropathic Pain
8. miR-155 and Neuropsychiatric Symptoms
9. Future Perspectives
10. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Mapping Multiple Sclerosis around the World Key Epidemiology Findings, Atlas of MS, 3rd ed.; The Multiple Sclerosis International Federation (MSIF): London, UK, 2020; Available online: www.atlasofms.org (accessed on 1 December 2020).
- Field, J.; Browning, S.R.; Johnson, L.J.; Danoy, P.; Varney, M.D.; Tait, B.D.; Gandhi, K.S.; Charlesworth, J.C.; Heard, R.N.; Stewart, G.J.; et al. A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. PLoS ONE 2010, 5, e13454. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Handel, A.E.; Williamson, A.J.; Disanto, G.; Handunnetthi, L.; Giovannoni, G.; Ramagopalan, S.V. An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. PLoS ONE 2010, 5, e12496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Handel, A.E.; Williamson, A.J.; Disanto, G.; Dobson, R.; Giovannoni, G.; Ramagopalan, S.V. Smoking and Multiple Sclerosis: An Updated Meta-Analysis. PLoS ONE 2011, 6, e16149. [Google Scholar] [CrossRef] [PubMed]
- O’Connell, R.M.; Rao, D.S.; Chaudhuri, A.A.; Baltimore, D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010, 10, 111–122. [Google Scholar] [CrossRef]
- Zhang, K.; Wang, Y.-W.; Wang, Y.-Y.; Song, Y.; Zhu, J.; Si, P.-C.; Ma, R. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene 2017, 619, 10–20. [Google Scholar] [CrossRef]
- Sheinerman, K.S.; Toledo, J.B.; Tsivinsky, V.G.; Irwin, D.; Grossman, M.; Weintraub, D.; Hurtig, H.I.; Chen-Plotkin, A.; Wolk, D.A.; McCluskey, L.F.; et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer’s Res. Ther. 2017, 9, 1–13. [Google Scholar] [CrossRef]
- Barwari, T.; Joshi, A.; Mayr, M. MicroRNAs in Cardiovascular Disease. J. Am. Coll. Cardiol. 2016, 68, 2577–2584. [Google Scholar] [CrossRef] [Green Version]
- Tribolet, L.; Kerr, E.; Cowled, C.; Bean, A.G.D.; Stewart, C.R.; Dearnley, M.; Farr, R.J. MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing. Front. Microbiol. 2020, 11, 1197. [Google Scholar] [CrossRef]
- Long, H.; Wang, X.; Chen, Y.; Wang, L.; Zhao, M.; Lu, Q. Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett. 2018, 428, 90–103. [Google Scholar] [CrossRef]
- Condrat, C.E.; Thompson, D.C.; Barbu, M.G.; Bugnar, O.L.; Boboc, A.; Cretoiu, D.; Suciu, N.; Cretoiu, S.M.; Voinea, S.C. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells 2020, 9, 276. [Google Scholar] [CrossRef] [Green Version]
- Moore, C.S.; Rao, V.T.; Durafourt, B.A.; Bedell, B.J.; Ludwin, S.K.; Bar-Or, A.; Antel, J.P. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann. Neurol. 2013, 74, 709–720. [Google Scholar] [CrossRef]
- Leng, R.-X.; Pan, H.-F.; Qin, W.-Z.; Chen, G.-M.; Ye, D.-Q. Role of microRNA-155 in autoimmunity. Cytokine Growth Factor Rev. 2011, 22, 141–147. [Google Scholar] [CrossRef]
- Seddiki, N.; Brezar, V.; Ruffin, N.; Lévy, Y.; Swaminathan, S. Role of miR-155 in the regulation of lymphocyte immune function and disease. Immunology 2014, 142, 32–38. [Google Scholar] [CrossRef]
- McCoy, C.E. miR-155 Dysregulation and Therapeutic Intervention in Multiple Sclerosis. In Advances in Experimental Medicine and Biology; Springer Science and Business Media LLC: Berlin, Germany, 2017; Volume 1024, pp. 111–131. [Google Scholar]
- Miller, E. Multiple Sclerosis. Chem. Biol. Pteridines Folates 2012, 724, 222–238. [Google Scholar] [CrossRef]
- Lublin, F.D.; Reingold, S.C. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996, 46, 907–911. [Google Scholar] [CrossRef]
- Kasper, L.H.; Shoemaker, J. Multiple sclerosis immunology: The healthy immune system vs. the MS immune system. Neurology 2009, 74, S2–S8. [Google Scholar] [CrossRef]
- Alvarez, J.I.; Cayrol, R.; Prat, A. Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta Mol. Basis Dis. 2011, 1812, 252–264. [Google Scholar] [CrossRef] [Green Version]
- Kamphuis, W.W.; Troletti, C.D.; Reijerkerk, A.A.; Romero, I.; De Vries, E.H. The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators. CNS Neurol. Disord. Drug Targets 2015, 14, 157–167. [Google Scholar] [CrossRef]
- Trapp, B.D.; Vignos, M.; Dudman, J.; Chang, A.; Fisher, E.; Staugaitis, S.M.; Battapady, H.; Mork, S.; Ontaneda, D.; Jones, E.S.; et al. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: A retrospective study. Lancet Neurol. 2018, 17, 870–884. [Google Scholar] [CrossRef] [Green Version]
- Mycko, M.P.; Cichalewska, M.; Cwiklinska, H.; Selmaj, K.W. miR-155-3p Drives the Development of Autoimmune Demyelination by Regulation of Heat Shock Protein 40. J. Neurosci. 2015, 35, 16504–16515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Losy, J.; Bartosik-Psujek, H.; Członkowska, A.; Kurowska, K.; Maciejek, Z.; Mirowska-Guzel, D.; Potemkowski, A.; Ryglewicz, D.; Stępień, A. Rekomendacje i Zalecenia Ekspertów 80 Leczenie stwardnienia rozsianego Zalecenia Polskiego Towarzystwa Neurologicznego. Polski Przegląd Neurologiczny 2016, 12, 80–95. Available online: www.ppn.viamedica.pl (accessed on 4 December 2020).
- De Courcy, J.; Liedgens, H.; Obradovic, M.; Holbrook, T.; Jakubanis, R. A burden of illness study for neuropathic pain in Europe. Clin. Outcomes Res. 2016, 8, 113–126. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Solaro, C.; Trabucco, E.; Uccelli, M.M. Pain and Multiple Sclerosis: Pathophysiology and Treatment. Curr. Neurol. Neurosci. Rep. 2012, 13, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Kalb, R.; Beier, M.; Benedict, R.H.; Charvet, L.; Costello, K.; Feinstein, A.; Gingold, J.; Goverover, Y.; Halper, J.; Harris, C.; et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult. Scler. J. 2018, 24, 1665–1680. [Google Scholar] [CrossRef] [Green Version]
- Paparrigopoulos, T.; Ferentinos, P.; Kouzoupis, A.; Koutsis, G.; Papadimitriou, G.N. The neuropsychiatry of multiple sclerosis: Focus on disorders of mood, affect and behaviour. Int. Rev. Psychiatry 2010, 22, 14–21. [Google Scholar] [CrossRef]
- Samkoff, L.M.; Goodman, A.D. Symptomatic Management in Multiple Sclerosis. Neurol. Clin. 2011, 29, 449–463. [Google Scholar] [CrossRef]
- Solomon, A.J.; Bourdette, D.N.; Cross, A.H.; Applebee, A.; Skidd, P.M.; Howard, D.B.; Spain, R.I.; Cameron, M.H.; Kim, E.; Mass, M.K.; et al. The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology 2016, 87, 1393–1399. [Google Scholar] [CrossRef]
- Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17, 162–173. [Google Scholar] [CrossRef]
- Housley, W.J.; Pitt, D.; Hafler, D.A. Biomarkers in multiple sclerosis. Clin. Immunol. 2015, 161, 51–58. [Google Scholar] [CrossRef]
- Giovannoni, G.; Tomic, D.; Bright, J.R.; Havrdová, E. “No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis. Mult. Scler. J. 2017, 23, 1179–1187. [Google Scholar] [CrossRef] [Green Version]
- Montalban, X.; Hauser, S.L.; Kappos, L.; Arnold, D.L.; Bar-Or, A.; Comi, G.; De Seze, J.; Giovannoni, G.; Hartung, H.-P.; Hemmer, B.; et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New Engl. J. Med. 2017, 376, 209–220. [Google Scholar] [CrossRef]
- Gajofatto, A.; Turatti, M. Siponimod to treat secondary progressive multiple sclerosis. Drugs Today 2020, 56, 37–46. [Google Scholar] [CrossRef]
- Wingerchuk, D.M.; Weinshenker, B.G. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016, 354, i3518. [Google Scholar] [CrossRef]
- Szelenberger, R.; Kacprzak, M.; Saluk-Bijak, J.; Zielinska, M.; Bijak, M. Plasma MicroRNA as a novel diagnostic. Clin. Chim. Acta 2019, 499, 98–107. [Google Scholar] [CrossRef]
- Otaegui, D.; Baranzini, S.E.; Armañanzas, R.; Calvo, B.; Muñoz-Culla, M.; Khankhanian, P.; Inza, I.; Lozano, J.A.; Castillo-Triviño, T.; Asensio, A.; et al. Differential Micro RNA Expression in PBMC from Multiple Sclerosis Patients. PLoS ONE 2009, 4, e6309. [Google Scholar] [CrossRef] [Green Version]
- Regev, K.; Paul, A.; Healy, B.; Von Glenn, F.; Diaz-Cruz, C.; Gholipour, T.; Mazzola, M.A.; Raheja, R.; Nejad, P.; Glanz, B.I.; et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016, 3, e267. [Google Scholar] [CrossRef] [Green Version]
- Baulina, N.M.; Kulakova, O.G.; Favorova, O.O. MicroRNAs: The Role in Autoimmune Inflammation. Acta Nat. 2016, 8, 21–33. [Google Scholar] [CrossRef]
- Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 2014, 15, 509–524. [Google Scholar] [CrossRef]
- Macias, S.; Cordiner, R.A.; Caceres, J.F. Cellular functions of the microprocessor. Biochem. Soc. Trans. 2013, 41, 838–843. [Google Scholar] [CrossRef] [Green Version]
- Song, M.-S.; Rossi, J.J. Molecular mechanisms of Dicer: Endonuclease and enzymatic activity. Biochem. J. 2017, 474, 1603–1618. [Google Scholar] [CrossRef] [Green Version]
- Meijer, H.A.; Smith, E.M.; Bushell, M. Regulation of miRNA strand selection: Follow the leader? Biochem. Soc. Trans. 2014, 42, 1135–1140. [Google Scholar] [CrossRef]
- Piket, E.; Zheleznyakova, G.Y.; Kular, L.; Jagodic, M. Small non-coding RNAs as important players, biomarkers and therapeutic targets in multiple sclerosis: A comprehensive overview. J. Autoimmun. 2019, 101, 17–25. [Google Scholar] [CrossRef]
- O’carroll, D.; Schaefer, A. General Principals of miRNA Biogenesis and Regulation in the Brain. Neuropsychopharmacology 2012, 38, 39–54. [Google Scholar] [CrossRef] [Green Version]
- Mahesh, G.; Biswas, R. MicroRNA-155: A Master Regulator of Inflammation. J. Interf. Cytokine Res. 2019, 39, 321–330. [Google Scholar] [CrossRef]
- Helwak, A.; Kudla, G.; Dudnakova, T.; Tollervey, D. Mapping the Human miRNA Interactome by CLASH Reveals Frequent Noncanonical Binding. Cell 2013, 153, 654–665. [Google Scholar] [CrossRef] [Green Version]
- Varma-Doyle, A.V.; Lukiw, W.J.; Zhao, Y.; Lovera, J.; Devier, D. A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways. J. Neurol. Sci. 2021, 420, 117202. [Google Scholar] [CrossRef]
- Luo, D.; Wang, J.; Zhang, X.; Rang, X.; Xu, C.; Fu, J. Identification and functional analysis of specific MS risk miRNAs and their target genes. Mult. Scler. Relat. Disord. 2020, 41, 102044. [Google Scholar] [CrossRef] [PubMed]
- Eis, P.S.; Tam, W.; Sun, L.; Chadburn, A.; Li, Z.; Gomez, M.F.; Lund, E.; Dahlberg, J.E. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 2005, 102, 3627–3632. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tam, W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene 2001, 274, 157–167. [Google Scholar] [CrossRef]
- Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A.O.; Landthaler, M.; et al. A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell 2007, 129, 1401–1414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rodriguez, A.; Vigorito, E.; Clare, S.; Warren, M.V.; Couttet, P.; Soond, D.R.; Van Dongen, S.; Grocock, R.J.; Das, P.P.; Miska, E.A.; et al. Requirement of bic/microRNA-155 for Normal Immune Function. Science 2007, 316, 608–611. [Google Scholar] [CrossRef] [Green Version]
- Gaudet, A.D.; Fonken, L.K.; Watkins, L.R.; Nelson, R.J.; Popovich, P.G. MicroRNAs: Roles in Regulating Neuroinflammation. Neuroscientist 2018, 24, 221–245. [Google Scholar] [CrossRef] [Green Version]
- Bradburn, S. Mechanisms Linking Depression, Immune System and Epigenetics During Aging. Inflamm. Immun. Depress. 2018, 339–356. [Google Scholar] [CrossRef]
- Slota, J.A.; Booth, S.A. MicroRNAs in Neuroinflammation: Implications in Disease Pathogenesis, Biomarker Discovery and Therapeutic Applications. Non Coding RNA 2019, 5, 35. [Google Scholar] [CrossRef] [Green Version]
- Ransohoff, R.M. How neuroinflammation contributes to neurodegeneration. Science 2016, 353, 777–783. [Google Scholar] [CrossRef]
- Cardoso, A.L.; Guedes, J.R.; De Almeida, L.P.; De Lima, M.C.P. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology 2011, 135, 73–88. [Google Scholar] [CrossRef]
- O’Connell, R.M.; Chaudhuri, A.A.; Rao, D.S.; Baltimore, D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. USA 2009, 106, 7113–7118. [Google Scholar] [CrossRef] [Green Version]
- Worm, J.; Stenvang, J.; Petri, A.; Frederiksen, K.S.; Obad, S.; Elmén, J.; Hedtjärn, M.; Straarup, E.M.; Hansen, J.B.; Kauppinen, S. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res. 2009, 37, 5784–5792. [Google Scholar] [CrossRef]
- Martinez-Nunez, R.T.; Louafi, F.; Sanchez-Elsner, T. The Interleukin 13 (IL-13) Pathway in Human Macrophages Is Modulated by MicroRNA-155 via Direct Targeting of Interleukin 13 Receptor α1 (IL13Rα1). J. Biol. Chem. 2011, 286, 1786–1794. [Google Scholar] [CrossRef] [Green Version]
- Su, W.; Hopkins, S.; Nesser, N.K.; Sopher, B.; Silvestroni, A.; Ammanuel, S.; Jayadev, S.; Möller, T.; Weinstein, J.; Garden, G.A. The p53 Transcription Factor Modulates Microglia Behavior through MicroRNA-Dependent Regulation of c-Maf. J. Immunol. 2014, 192, 358–366. [Google Scholar] [CrossRef]
- Junker, A.; Krumbholz, M.; Eisele, S.; Mohan, H.; Augstein, F.; Bittner, R.A.; Lassmann, H.; Wekerle, H.; Hohlfeld, R.; Meinl, E. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009, 132, 3342–3352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Paraboschi, E.M.; Soldà, G.; Gemmati, D.; Orioli, E.; Zeri, G.; Benedetti, M.D.; Salviati, A.; Barizzone, N.; Leone, M.; Duga, S.; et al. Genetic Association and Altered Gene Expression of Mir-155 in Multiple Sclerosis Patients. Int. J. Mol. Sci. 2011, 12, 8695–8712. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Murugaiyan, G.; Beynon, V.; Mittal, A.; Joller, N.; Weiner, H.L. Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis. J. Immunol. 2011, 187, 2213–2221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gavgani, F.M.; Arnesen, V.S.; Jacobsen, R.G.; Krakstad, C.; Hoivik, E.A.; Lewis, A.E. Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer. Int. J. Mol. Sci. 2018, 19, 3931. [Google Scholar] [CrossRef] [Green Version]
- Urick, M.E.; Rudd, M.L.; Godwin, A.K.; Sgroi, D.C.; Merino, M.J.; Bell, D.W. PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer. Cancer Res. 2011, 71, 4061–4067. [Google Scholar] [CrossRef] [Green Version]
- Ma, X.; Zhou, J.; Zhong, Y.; Jiang, L.; Mu, P.; Li, Y.; Singh, N.; Nagarkatti, M.; Nagarkatti, P. Expression, Regulation and Function of MicroRNAs in Multiple Sclerosis. Int. J. Med. Sci. 2014, 11, 810–818. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Cheng, Y.; Cui, W.; Li, M.; Li, B.; Guo, L. MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2014, 266, 56–63. [Google Scholar] [CrossRef]
- Ksiazek-Winiarek, D.; Szpakowski, P.; Turniak, M.; Szemraj, J.; Glabinski, A. IL-17 Exerts Anti-Apoptotic Effect via miR-155-5p Downregulation in Experimental Autoimmune Encephalomyelitis. J. Mol. Neurosci. 2017, 63, 320–332. [Google Scholar] [CrossRef] [Green Version]
- Ksiazek-Winiarek, D.J.; Kacperska, M.J.; Glabinski, A. MicroRNAs as Novel Regulators of Neuroinflammation. Mediat. Inflamm. 2013, 2013, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Lopez-Ramirez, M.A.; Wu, D.; Pryce, G.; Simpson, J.E.; Reijerkerk, A.; King-Robson, J.; Kay, O.; De Vries, H.E.; Hirst, M.C.; Sharrack, B.; et al. MicroRNA-155 negatively affects blood–brain barrier function during neuroinflammation. FASEB J. 2014, 28, 2551–2565. [Google Scholar] [CrossRef]
- Fonken, L.K.; Gaudet, A.D.; Gaier, K.R.; Nelson, R.J.; Popovich, P.G. MicroRNA-155 deletion reduces anxiety- and depressive-like behaviors in mice. Psychoneuroendocrinology 2016, 63, 362–369. [Google Scholar] [CrossRef] [PubMed]
- Niwald, M.; Migdalska-Sęk, M.; Brzeziańska-Lasota, E.; Miller, E. Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability. J. Mol. Neurosci. 2017, 63, 275–282. [Google Scholar] [CrossRef]
- Shademan, B.; Nourazarian, A.; Nikanfar, M.; Avci, C.B.; Hasanpour, M.; Isazadeh, A. Investigation of the miRNA146a and miRNA155 gene expression levels in patients with multiple sclerosis. J. Clin. Neurosci. 2020, 78, 189–193. [Google Scholar] [CrossRef]
- Zhang, Y.; Chen, Q.; Nai, Y.; Cao, C. Suppression of miR-155 attenuates neuropathic pain by inducing an M1 to M2 switch in microglia. Folia Neuropathol. 2020, 58, 70–82. [Google Scholar] [CrossRef]
- Daneman, R.; Prat, A. The Blood–Brain Barrier. Cold Spring Harb. Perspect. Biol. 2015, 7, a020412. [Google Scholar] [CrossRef] [Green Version]
- Ma, F.; Zhang, X.; Yin, K.-J. MicroRNAs in central nervous system diseases: A prospective role in regulating blood-brain barrier integrity. Exp. Neurol. 2020, 323, 113094. [Google Scholar] [CrossRef]
- Cerutti, C.; Soblechero-Martin, P.; Wu, D.; Lopez-Ramirez, M.A.; De Vries, H.; Sharrack, B.; Male, D.K.; Romero, I.A. MicroRNA-155 contributes to shear-resistant leukocyte adhesion to human brain endothelium in vitro. Fluids Barriers CNS 2016, 13, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muoio, V.; Persson, P.B.; Sendeski, M.M. The neurovascular unit—Concept review. Acta Physiol. 2014, 210, 790–798. [Google Scholar] [CrossRef]
- Lopez-Ramirez, M.A.; Reijerkerk, A.; De Vries, H.E.; Romero, I.A. Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation. FASEB J. 2016, 30, 2662–2672. [Google Scholar] [CrossRef] [Green Version]
- Caballero-Garrido, E.; Pena-Philippides, J.C.; Lordkipanidze, T.; Bragin, D.; Yang, Y.; Erhardt, E.B.; Roitbak, T. In Vivo Inhibition of miR-155 Promotes Recovery after Experimental Mouse Stroke. J. Neurosci. 2015, 35, 12446–12464. [Google Scholar] [CrossRef] [Green Version]
- Rom, S.; Dykstra, H.; Zuluaga-Ramirez, V.; Reichenbach, N.L.; Persidsky, Y. miR-98 and let-7g* Protect the Blood-Brain Barrier Under Neuroinflammatory Conditions. Br. J. Pharmacol. 2015, 35, 1957–1965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pena-Philippides, J.C.; Gardiner, A.S.; Caballero-Garrido, E.; Pan, R.; Zhu, Y.; Roitbak, T. Inhibition of MicroRNA-155 Supports Endothelial Tight Junction Integrity Following Oxygen-Glucose Deprivation. J. Am. Heart Assoc. 2018, 7, e009244. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, T.; Zhou, S.; Li, X.; Song, J.; An, T.; Huang, X.; Ping, X.; Wang, L. microRNA 155 induces protection against cerebral ischemia/reperfusion injury through regulation of the Notch pathway in vivo. Exp. Ther. Med. 2019, 18, 605–613. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Almutairi, M.M.A.; Gong, C.; Xu, Y.G.; Chang, Y.; Shi, H. Factors controlling permeability of the blood–brain barrier. Cell. Mol. Life Sci. 2016, 73, 57–77. [Google Scholar] [CrossRef]
- Luo, C.; Jian, C.; Liao, Y.; Huang, Q.; Wu, Y.; Liu, X.; Zou, D.; Wu, Y. The role of microglia in multiple sclerosis. Neuropsychiatr. Dis. Treat. 2017, 13, 1661–1667. [Google Scholar] [CrossRef] [Green Version]
- Mycko, M.P.; Cichalewska, M.; Machlanska, A.; Cwiklinska, H.; Mariasiewicz, M.; Selmaj, K.W. microRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc. Natl. Acad. Sci. USA 2012, 109, E1248–E1257. [Google Scholar] [CrossRef] [Green Version]
- Hu, R.; Huffaker, T.B.; Kagele, D.A.; Runtsch, M.C.; Bake, E.; Chaudhuri, A.A.; Round, J.L.; O’Connell, R.M. MicroRNA-155 Confers Encephalogenic Potential to Th17 Cells by Promoting Effector Gene Expression. J. Immunol. 2013, 190, 5972–5980. [Google Scholar] [CrossRef]
- Mazloumfard, F.; Mirian, M.; Eftekhari, S.-M.; Aliomrani, M. Hydroxychloroquine effects on miR-155-3p and miR-219 expression changes in animal model of multiple sclerosis. Metab. Brain Dis. 2020, 35, 1–9. [Google Scholar] [CrossRef]
- Gholami, S.; Mirian, M.; Eftekhari, S.M.; Aliomrani, M. Apamin administration impact on miR-219 and miR-155-3p expression in cuprizone induced multiple sclerosis model. Mol. Biol. Rep. 2020, 47, 9013–9019. [Google Scholar] [CrossRef]
- Digehsara, S.G.; Name, N.; Esfandiari, B.; Karim, E.; Taheri, S.; Tajabadi-Ebrahimi, M.; Arasteh, J. Effects of Lactobacillus casei Strain T2 (IBRC-M10783) on the Modulation of Th17/Treg and Evaluation of miR-155, miR-25, and IDO-1 Expression in a Cuprizone-Induced C57BL/6 Mouse Model of Demyelination. Inflammation 2021, 44, 334–343. [Google Scholar] [CrossRef]
- Han, S.R.; Kang, Y.H.; Jeon, H.; Lee, S.; Park, S.J.; Song, D.-Y.; Min, S.S.; Yoo, S.-M.; Lee, S.; Lee, M.-S.; et al. Differential Expression of miRNAs and Behavioral Change in the Cuprizone-Induced Demyelination Mouse Model. Int. J. Mol. Sci. 2020, 21, 646. [Google Scholar] [CrossRef] [Green Version]
- Vallejo, R.; Tilley, D.M.; Vogel, L.; Benyamin, R. The Role of Glia and the Immune System in the Development and Maintenance of Neuropathic Pain. Pain Pract. 2010, 10, 167–184. [Google Scholar] [CrossRef]
- Ledeboer, A.; Gamanos, M.; Lai, W.; Martín, D.; Maier, S.F.; Watkins, L.R.; Quan, N. Involvement of spinal cord nuclear factor κB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur. J. Neurosci. 2005, 22, 1977–1986. [Google Scholar] [CrossRef]
- Xu, L.; Huang, Y.; Yu, X.; Yue, J.; Yang, N.; Zuo, P. The Influence of p38 Mitogen-Activated Protein Kinase Inhibitor on Synthesis of Inflammatory Cytokine Tumor Necrosis Factor Alpha in Spinal Cord of Rats with Chronic Constriction Injury. Anesthesia Analg. 2007, 105, 1838–1844. [Google Scholar] [CrossRef]
- Pohl, K.-W.; Yeol, J.-F.; Ongl, W.-Y. MicroRNA changes in the mouse prefrontal cortex after inflammatory pain. Eur. J. Pain 2011, 15, 801.e1–801.e12. [Google Scholar] [CrossRef]
- Tan, Y.; Yang, J.; Xiang, K.; Tan, Q.; Guo, Q. Suppression of MicroRNA-155 Attenuates Neuropathic Pain by Regulating SOCS1 Signalling Pathway. Neurochem. Res. 2014, 40, 550–560. [Google Scholar] [CrossRef]
- Liu, S.; Zhu, B.; Sun, Y.; Xie, X. miR-155 modulates the progression of neuropathic pain through targeting SGK3. Int. J. Clin. Exp. Pathol. 2015, 8, 14374–14382. [Google Scholar]
- Heyn, J.; Luchting, B.; Hinske, L.C.; Hübner, M.; Azad, S.C.; Kreth, S. miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. J. Neuroinflamm. 2016, 13, 1–11. [Google Scholar] [CrossRef] [Green Version]
- Sabirzhanov, B.; Li, Y.; Coll-Miro, M.; Matyas, J.J.; He, J.; Kumar, A.; Ward, N.; Yu, J.; Faden, A.I.; Wu, J. Inhibition of NOX2 signaling limits pain-related behavior and improves motor function in male mice after spinal cord injury: Participation of IL-10/miR-155 pathways. Brain Behav. Immun. 2019, 80, 73–87. [Google Scholar] [CrossRef]
- Kumar, A.; Barrett, J.P.; Alvarez-Croda, D.-M.; Stoica, B.A.; Faden, A.I.; Loane, D.J. NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury. Brain Behav. Immun. 2016, 58, 291–309. [Google Scholar] [CrossRef] [Green Version]
- Choi, S.-H.; Aid, S.; Kim, H.-W.; Jackson, S.H.; Bosetti, F. Inhibition of NADPH oxidase promotes alternative and anti-inflammatory microglial activation during neuroinflammation. J. Neurochem. 2012, 120, 292–301. [Google Scholar] [CrossRef]
- Kim, D.; You, B.; Jo, E.-K.; Han, S.-K.; Simon, M.I.; Lee, S.J. NADPH oxidase 2-derived reactive oxygen species in spinal cord microglia contribute to peripheral nerve injury-induced neuropathic pain. Proc. Natl. Acad. Sci. USA 2010, 107, 14851–14856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hassler, S.N.; Johnson, K.M.; Hulsebosch, C.E. Reactive oxygen species and lipid peroxidation inhibitors reduce mechanical sensitivity in a chronic neuropathic pain model of spinal cord injury in rats. J. Neurochem. 2014, 131, 413–417. [Google Scholar] [CrossRef] [Green Version]
- McCoy, C.E.; Sheedy, F.J.; Qualls, J.E.; Doyle, S.L.; Quinn, S.R.; Murray, P.J.; O’Neill, L.A. IL-10 Inhibits miR-155 Induction by Toll-like Receptors. J. Biol. Chem. 2010, 285, 20492–20498. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, X.; Wang, D.; Zhou, J.; Yan, Y.; Chen, L. Evaluation of circulating microRNA expression in patients with trigeminal neuralgia. Medicine 2020, 99, e22972. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Li, C.; Liu, W.; Yan, B.; Hu, X.; Yang, F. miRNA-155 silencing reduces sciatic nerve injury in diabetic peripheral neuropathy. J. Mol. Endocrinol. 2019, 63, 227–238. [Google Scholar] [CrossRef] [PubMed]
- Patten, S.B.; Marrie, R.A.; Carta, M.G. Depression in multiple sclerosis. Int. Rev. Psychiatry 2017, 29, 463–472. [Google Scholar] [CrossRef]
- Brites, D.; Fernandes, A. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Front. Cell. Neurosci. 2015, 9, 476. [Google Scholar] [CrossRef] [Green Version]
- Pittenger, C.; Duman, R.S. Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms. Neuropsychopharmacology 2008, 33, 88–109. [Google Scholar] [CrossRef]
- Wan, Y.; Liu, Y.; Wang, X.; Wu, J.; Liu, K.; Zhou, J.; Liu, L.; Zhang, C. Identification of Differential MicroRNAs in Cerebrospinal Fluid and Serum of Patients with Major Depressive Disorder. PLoS ONE 2015, 10, e0121975. [Google Scholar] [CrossRef]
- Wang, X.; Wang, B.; Zhao, J.; Liu, C.; Qu, X.; Li, Y. MiR-155 is involved in major depression disorder and antidepressant treatment via targeting SIRT1. Biosci. Rep. 2018, 38. [Google Scholar] [CrossRef] [Green Version]
- Sun, X.; Song, M.; Song, H.; Wang, Y.; Luo, M.; Yin, L. miR 155 mediates inflammatory injury of hippocampal neuronal cells via the activation of microglia. Mol. Med. Rep. 2019, 19, 2627–2635. [Google Scholar] [CrossRef]
- Gerrard, B.; Singh, V.; Babenko, O.; Gauthier, I.; Yong, V.W.; Kovalchuk, I.; Luczak, A.; Metz, G.A. Chronic mild stress exacerbates severity of experimental autoimmune encephalomyelitis in association with altered non-coding RNA and metabolic biomarkers. Neuroscience 2017, 359, 299–307. [Google Scholar] [CrossRef]
- Liguori, M.; Nuzziello, N.; Simone, M.; Amoroso, N.; Viterbo, R.G.; Tangaro, S.; Consiglio, A.; Giordano, P.; Bellotti, R.; Trojano, M. Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study. Brain Behav. 2019, 9, e01199. [Google Scholar] [CrossRef] [Green Version]
- Tili, E.; Mezache, L.; Michaille, J.-J.; Amann, V.; Williams, J.; Vandiver, P.; Quinonez, M.; Fadda, P.; Mikhail, A.; Nuovo, G. microRNA 155 up regulation in the CNS is strongly correlated to Down’s syndrome dementia. Ann. Diagn. Pathol. 2018, 34, 103–109. [Google Scholar] [CrossRef]
- Liu, D.; Zhao, D.; Zhao, Y.; Wang, Y.; Zhao, Y.; Wen, C. Inhibition of microRNA-155 Alleviates Cognitive Impairment in Alzheimer’s Disease and Involvement of Neuroinflammation. Curr. Alzheimer Res. 2019, 16, 473–482. [Google Scholar] [CrossRef]
- Wei, H.; Xu, Y.; Xu, W.; Zhou, Q.; Chen, Q.; Yang, M.; Feng, F.; Liu, Y.; Zhu, X.; Yu, M.; et al. Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia. Neuroscience 2018, 379, 167–176. [Google Scholar] [CrossRef]
- Liddelow, S.A.; Guttenplan, K.A.; Clarke, L.E.; Bennett, F.C.; Bohlen, C.J.; Schirmer, L.; Bennett, M.L.; Münch, A.E.; Chung, W.-S.; Peterson, T.C.; et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017, 541, 481–487. [Google Scholar] [CrossRef]
- ClinicalTrials.gov. MicroRNA-150 and microRNA-155 in Multiple Sclerosis—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT04300543?term=miR-155&cond=Multiple+Sclerosis&draw=2&rank=1 (accessed on 2 April 2021).
- ClinicalTrials.gov. SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects with Mycosis Fungoides—Tabular View. Available online: https://clinicaltrials.gov/ct2/show/record/NCT03713320 (accessed on 2 April 2021).
- ClinicalTrials.gov. PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Mycosis Fungoides Who Have Completed the SOLAR Study—Full Text View. Available online: https://clinicaltrials.gov/ct2/show/NCT03837457 (accessed on 2 April 2021).
- Witten, L.; Slack, F.J. miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis 2019, 41, 2–7. [Google Scholar] [CrossRef]
- Sheinerman, K.S.; Umansky, S.R. Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front. Cell. Neurosci. 2013, 7, 150. [Google Scholar] [CrossRef] [Green Version]
- Chakraborty, C.; Sharma, A.R.; Sharma, G.; Lee, S.-S. Therapeutic advances of miRNAs: A preclinical and clinical update. J. Adv. Res. 2021, 28, 127–138. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maciak, K.; Dziedzic, A.; Miller, E.; Saluk-Bijak, J. miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. Int. J. Mol. Sci. 2021, 22, 4332. https://doi.org/10.3390/ijms22094332
Maciak K, Dziedzic A, Miller E, Saluk-Bijak J. miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review. International Journal of Molecular Sciences. 2021; 22(9):4332. https://doi.org/10.3390/ijms22094332
Chicago/Turabian StyleMaciak, Karina, Angela Dziedzic, Elzbieta Miller, and Joanna Saluk-Bijak. 2021. "miR-155 as an Important Regulator of Multiple Sclerosis Pathogenesis. A Review" International Journal of Molecular Sciences 22, no. 9: 4332. https://doi.org/10.3390/ijms22094332